Recalcitrant lichen planopilaris and frontal fibrosing alopecia responding to tildrakizumab.
frontal fibrosing alopecia
lichen planopilaris
tildrakizumab
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
19
12
2019
revised:
07
05
2020
accepted:
25
05
2020
pubmed:
28
5
2020
medline:
15
5
2021
entrez:
28
5
2020
Statut:
ppublish
Résumé
Lichen planopilaris (LPP) and frontal fibrosing alopecia (FFA) are lymphocytic, cicatricial alopecias. Clinically, LPP presents with multifocal patchy alopecia, while FFA, considered a variant of LPP, results in hairline recession. Frontal recession in FFA may progress as far as the mid-scalp and infrequently beyond. Treatment to arrest the inflammatory process can be challenging and response variable. We report a case of recalcitrant lichen planopilaris and frontal fibrosing alopecia demonstrating significant clinical improvement after four doses of the interleukin-23 monoclonal antibody tildrakizumab.
Substances chimiques
Antibodies, Monoclonal, Humanized
0
tildrakizumab
DEW6X41BEK
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13694Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Moreno-Arrones OM, Saceda-Corralo D, Rodrigues-Barata AR, et al. Risk factors associated with frontal fibrosing alopecia: a multicentre case-control study. Clin Exp Dermatol. 2019;44:404-410.
Aldoori N, Dobson K, Holden CR, McDonagh AJ, Harries M, Messenger AG. Frontal fibrosing alopecia: possible association with leave-on facial skin care products and sunscreens; a questionnaire study. Br J Dermatol. 2016;175:762-767.
Iorizzo M, Tosti A. Frontal fibrosing alopecia: an update on pathogenesis, diagnosis, and treatment. Am J Clin Dermatol. 2019;20:379-390. https://doi.org/10.1007/s40257-019-00424-y.
Cranwell WC, Sinclair R. Sunscreen and facial skincare products in frontal fibrosing alopecia: a case-control study. Br J Dermatol. 2019;180:943-944.
Tan KT, Messenger AG. Frontal fibrosing alopecia: clinical presentations and prognosis. Br J Dermatol. 2009;160:75-79.
Tosti A, Piraccini BM, Iorizzo M, Misciali C. Frontal fibrosing alopecia in postmenopausal women. J Am Acad Dermatol. 2005;52:55-60.
Kossard S, Lee M-S, Wilkinson B. Postmenopausal frontal fibrosing alopecia: a frontal variant of lichen planopilaris. J Am Acad Dermatol. 1997;36(1):59-66.
Valesky EM, Maier MD, Kaufmann R, Zöller N, Meissner M. Single-center analysis of patients with frontal fibrosing alopecia: evidence for hypothyroidism and a good quality of life. J Int Med Res. 2019 Feb;47(2):653-661.
Tziotzios C, Petridis C, Dand N, et al. Genome-wide association study in frontal fibrosing alopecia identifies four susceptibility loci including HLA-B*07:02. Nat Commun. 2019;10:1150. https://doi.org/10.1038/s41467-019-09117-w.
Racz E, Gho C, Moorman PW, Noordhoek Hegt V, Neumann HA. Treatment of frontal fibrosing alopecia and lichen planopilaris: a systematic review. J Eur Acad Dermatol Venereol. 2013;27:1461-1470.
Kolli SS, Gabros SD, Pona A, Cline A, Feldman SR. Tildrakizumab: a review of phase II and III clinical trials. Ann Pharmacother. 2019;53:413-418.
Lu R, Zeng X, Han Q, Lin M., Long L., Dan H., Zhou G., Chen Q. Overexpression and selectively regulatory roles of IL-23/IL-17 axis in the lesions of oral lichen planus. Mediators Inflamm 2014;2014:701094.
Shen Z, Gao X, Ma L, Zhou Z, Shen X, Liu W. Expression of Foxp3 and interleukin-17 in lichen planus lesions with emphasis on difference in oral and cutaneous variants. Arch Dermatol Res. 2014;306:441-446.